Skip to content
Screener

Vaxcyte, Inc. PCVX Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

EPS-$1.80Miss by $0.27
Revenue estimate$18.8M
EPS estimate-$1.53

Next report

Nov 3, 2026 (in 3 months)
Revenue estimate$12.5M
EPS estimate-$2.12

Financials

Q4 2025

Income statement

See full
Operating income-$274.3M-69.1%
Net income-$246.5M-79.8%
EPS (diluted)-$1.80-76.5%

Balance sheet

See full
Cash & equivalents$175.4M-54.9%
Total debt$117.6M+65.4%
Total equity$2.7B-18.8%
Total assets$3.0B-14.5%

Cash flow

See full
Operating cash flow-$224.8M-102%
CapEx$2.7M-34.0%
Free cash flow-$227.5M-97.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$6.04B-40.8%
Enterprise value$5.98B-39.5%

Returns & leverage

See full
Return on equity-25.6%+8.7pp
Debt / equity0×0.0×
Current ratio7.9×-4.8×

FAQ

When did Vaxcyte, Inc. report Q4 2025 earnings?
Vaxcyte, Inc. (PCVX) reported Q4 2025 earnings on February 24, 2026 after market close.
What were Vaxcyte, Inc.'s Q4 2025 revenue and EPS?
Vaxcyte, Inc. reported eps of $-1.80 for Q4 2025.
Did Vaxcyte, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-1.53 by $0.27.
How did Vaxcyte, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 76.5% from $-1.02.
Where can I find Vaxcyte, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001649094-26-000005) and the 10-K periodic report (0001649094-26-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.